In August 2026, Eli Lilly did something it had resisted for months: it formalised a pre-approval access pathway for retatrutide, its investigational triple-agonist, so that doctors could request the drug for individual patients outside a clinical trial. Australian readers immediately asked the obvious question — does our Special Access Scheme do the same thing here? The honest answer is that retatrutide TGA approval and Australian early access are two separate problems, and the second one is not solved by the first pathway most people assume.

What Lilly actually opened in August 2026

The programme is an expanded access arrangement, registered on ClinicalTrials.gov as a pre-approval expanded access record (NCT07629401). Reporting from STAT and Medscape describes it as a response to weeks of physician inquiries after a single patient had earlier been granted access.

The published eligibility criteria are narrow. A patient must have refractory obesity — a BMI of 35 or above despite adherence to, and tolerance of, the highest available dose of an approved chronic weight management therapy — plus two or more serious or life-threatening obesity-related complications currently being treated to standard of care. They must also be unable to participate in an ongoing retatrutide trial (or a comparable investigational study), and all standard options including bariatric surgery must have been discussed through shared decision-making.

Requests are initiated by the treating physician, not the patient. Lilly's role is to sponsor the access, or to authorise the FDA to cross-reference its investigational new drug file on the requesting physician's behalf. That last detail is the tell: the mechanism is built on a US regulatory instrument.

Retatrutide TGA approval: where the file actually sits

Retatrutide is not on the Australian Register of Therapeutic Goods, and as of this month no medicines regulator anywhere has approved it. Reported plans put Lilly's first regulatory filing from 2027, with a US submission signalled for early that year. A TGA submission would follow its own timeline, and nothing in the public record sets a date for it.

That matters because Australia's unapproved-goods pathways were designed around products that exist somewhere in the supply chain. Retatrutide's only legitimate supply chain today is the trial programme. You can read our background on what retatrutide is and the phase 3 evidence base for context on why demand is running ahead of the file — TRIUMPH-1 reported up to about 28.3% average body weight loss at 12mg over 80 weeks, with 45.3% of participants losing 30% or more.

Why SAS Category B is not the Australian version of expanded access

The Special Access Scheme Category B pathway does let a practitioner apply to the TGA to supply an unapproved medicine to a named patient, with written clinical justification. Approval is not automatic, and the TGA issues an approval number by letter if it agrees.

Here is the part that gets skipped. TGA guidance is explicit that suppliers are under no obligation to supply an unapproved product, regardless of whether the TGA has approved, authorised or been notified of the request. The guidance goes further and advises practitioners to check with the sponsor before lodging an application, to confirm the sponsor will actually supply. A TGA approval letter is a permission, not a delivery. State and territory requirements for lawful supply also continue to apply on top of it.

So an Australian SAS Category B approval for retatrutide would still depend entirely on Lilly agreeing to release product into Australia — which is the same decision that governs the US programme, just reached through a different door.

The criterion that bites hardest in Australia

One of Lilly's four eligibility conditions is that the patient cannot participate in an ongoing retatrutide trial, whether because of the protocol's exclusion criteria or because there is no reasonably accessible enrolling site.

Australia is unusually well covered on that measure. The TRIUMPH-Outcomes cardiovascular and kidney outcomes study (NCT06383390) — an event-driven trial of roughly 10,000 participants with an estimated completion date of February 2029 — lists Australian sites across every mainland state and the ACT, including the Alfred and Box Hill in Melbourne, Royal Brisbane and Women's, Royal North Shore and the Charles Perkins Centre in Sydney, Fiona Stanley in Perth, Canberra Hospital, Barwon Health in Geelong and Southern Adelaide Diabetes and Endocrine Services. TRIUMPH-3, in severe obesity with established cardiovascular disease, also runs Australian sites.

That density cuts both ways. For a patient with obesity and atherosclerotic cardiovascular disease or chronic kidney disease, a geographically accessible site may well exist — which is the legitimate route to supervised access, but also the reason a compassionate-use argument is harder to make on "no accessible site" grounds. Individual protocol eligibility is still a clinical assessment, and enrolment status at any given site changes; the trial registry entry is the only reliable check.

What Australians should take from this

The August announcement is real news, but it is a US programme with US-shaped plumbing and criteria that, by design, most people will not meet. It does not change retatrutide's status here. Our Australia page tracks the regulatory position, and the safety overview covers what the trial data has reported to date — including the gastrointestinal tolerability profile that sits behind the dose-escalation schedules used in TRIUMPH.

Want the next development on the TGA file as it happens? Join the free updates list.

FAQ

Is retatrutide TGA approved in Australia?

No. Retatrutide is investigational, is not on the Australian Register of Therapeutic Goods, and has not been approved by the TGA or any other medicines regulator. Reported plans put Lilly's first regulatory filings from 2027.

Can my doctor get retatrutide on the Special Access Scheme?

A practitioner can lodge an SAS Category B application with clinical justification, but TGA guidance is clear that a supplier is under no obligation to supply an unapproved product even if the TGA approves the request. The TGA advises confirming with the sponsor before applying.

Does Eli Lilly's expanded access program cover Australia?

The programme announced in August 2026 is a US pre-approval expanded access arrangement, initiated by the treating physician and built around a US investigational new drug file. Its published criteria require refractory obesity with a BMI of 35 or above, two or more serious obesity-related complications, and inability to join an ongoing retatrutide trial.

Are there retatrutide clinical trials in Australia?

Yes. The TRIUMPH-Outcomes cardiovascular and kidney study lists Australian sites in New South Wales, Victoria, Queensland, South Australia, Western Australia and the ACT, and TRIUMPH-3 also runs Australian sites. Enrolment status changes, so the ClinicalTrials.gov registry entry is the place to check.

Sources

This article is independent editorial content and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company. Retatrutide is an investigational medicine and is not approved by the TGA or any other regulator. Nothing here is medical advice — talk to a qualified Australian health practitioner about your own circumstances before making any treatment decision.